Adrenergic overload and apoptosis in heart failure: implications for therapy

Area of Science:

• Cardiology
• Molecular Biology
• Pathophysiology

Background:

• Sympathetic nervous system overactivity and norepinephrine (NE) contribute to heart failure progression.
• NE can directly harm cardiac myocytes, promoting pathological remodeling and left ventricular (LV) dysfunction.
• Apoptosis (programmed cell death) of cardiac myocytes is observed in failing human hearts, suggesting a mechanism for progressive failure.

Purpose of the Study:

• To investigate the role of norepinephrine and beta-adrenergic receptors (beta-ARs) in cardiac myocyte apoptosis.
• To explore the differential signaling of beta1-AR versus beta2-AR in catecholamine-induced myocyte apoptosis.
• To provide a mechanistic basis for the potential therapeutic use of beta-AR antagonists in heart failure.

Main Methods:

• In vitro studies using cultured cardiac myocytes exposed to NE.
• In vivo studies involving isoproterenol infusion in rats.
• Studies using genetically modified mice overexpressing beta1-AR or G alpha s in the myocardium.

Main Results:

• Tonic NE exposure increased cardiac myocyte apoptosis through the beta-AR pathway.
• A beta1-AR selective antagonist prevented NE-induced apoptosis, while a beta2-AR antagonist exacerbated it.
• Isoproterenol infusion in rats increased TUNEL-positive myocytes; cardiac-specific beta1-AR or G alpha s overexpression led to LV dilation, dysfunction, and apoptosis.

Conclusions:

• Norepinephrine-induced cardiac myocyte apoptosis is mediated by beta-AR signaling.
• Beta1-AR and beta2-AR exhibit distinct roles in catecholamine-induced apoptosis.
• These findings support a mechanism by which beta-AR antagonists could mitigate LV remodeling and heart failure.